Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOA-08: Temozolomide vs Radiotherapy in Elderly with Anaplastic Astrocytoma or Glioblastoma
NCT01502241Phase 3Completed
- Sponsor
- Heidelberg University
- Start
- Jan 2005
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of temozolomide in glioblastoma (GBM) and anaplastic astrocytoma (AA) (2 arms), sponsored by Heidelberg University. Primary endpoint: Overall Survival at 12 months. Started Jan 2005; status: completed.
02
Drugs
temozolomide
03
Conditions
glioblastoma (GBM)anaplastic astrocytoma (AA)
Beyond the preview
Go deeper on NCT01502241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01502241.